Search

Amaç: Bu çalışmada Bursa ilinde Alzheimer hastalarına bakım veren bireylerin hastalıkla ilgili farkındalık düzeyinin araştırılması amaçlanmıştır. Gereç ve Yöntem: Orta veya ağır evre Alzheimer hastasına en az 6 aydır bire bir bakım veren 50 kişi çalışmaya dahil edildi. Hastaların ve bakım verenlerin demografik özellikleri kayıt altına alındı. Bakım verenlere hastalıkla ilgili basit temel bilgilerin sorgulandığı 10 soruluk bir anket uygulandı. Bulgular: Katılımcıların %56’sı hastalıkla karşılaşmadan önce hastalıkla ilgili bilgiye sahip değildi. %50’si yakını Alzheimer tanısı aldıktan sonra hastalıkla ilgili bilgi almak için herhangi bir yönteme başvurmamıştı. Katılımcıların %84’ü hastalığın kalıcı olduğunu, %80’i tedavisinin ilaçlarla yapıldığını bilmekteydi. %86’sı ilaçların şikayetleri sadece kısmen geriletmek için verildiğinin farkındaydı. %54’ü ağızdan alınan tabletler dışında başka tedavi seçeneklerinden haberdar değildi. %44’ü tedaviyle hastalığın düzelmediğini, %50’si ilaçları dönem dönem değiştirmek gerektiğini bilmekteydi. Hastalıkla ilgili sizi en çok sıkıntıya sokan şey nedir sorusuna sırasıyla gece uykusuzluğu, ajitasyonlar, inatçılık, hırçınlık, idrar ve gaita inkontinansı cevapları verildi. Sonuç: Hasta yakınlarının hastalıkla ilgili yeterli bilgiye sahip olması hastalığın erken tanınması, hastalığa bağlı gelişen problemlerin anlaşılabilmesi ve tedavi sürecinin düzgün yönetilmesine olanak sağlayacaktır., Objective: The aim of the study is to investigate the level of knowledge of Alzheimer Disease (AD) among caregivers in Bursa. Material and Methods: 50 caregivers who were taking care of medium or sever Alzheimer patient at least for six months one to one were included to the study. The demographic characteristics of patients and caregivers were reported. A survey consisted of 10 questions which question basic main data about the illness was applied to caregivers. Results: %56 of participants did not have knowledge about the illness before they met the disease. %50 of caregivers did not try any methods after the patients diagnosed with Alzheimer. %84 of the participants knew that the disease was persistent and %80 of them knew that the treatment was made by medicines. %86 of them realize that the medicines was given only to back space the disease. %54 of them was unposted about the treatment alternatives except oral tablets. %44 of them knew that the disease did not get better with medicine and %50 of them knew that they have to change the medicine time to time. When we asked the most thing that worry the caregivers the answers were sleeplessness, agitation, tenacity, irritability, urine and fecal incontinence. Conclusion: The enough knowledge of caregivers about the illness may provide facility to early diagnosis, understand problems about the illness, manage the treatment process.

INTRODUCTION: In this study, we aimed to discuss the data of patients with acute ischemic stroke with intravenous thrombolytic therapy (IV-tPA) in our clinic in the light of the literature. METHODS: Seventy patients with acute ischemic stroke diagnosed between April 2016 and 2017 who received IV-tPA were included in the study. Demographic, radiological and clinical data of the patients were recorded. The intracranial hemorrhages and neurological status at the end of the third month were evaluated with the modified MRS score and the National Stroke Health Scale (NIHSS) scores within 3 months after discharge. The values of the symptom-needle time, the Alberta stroke program, the early computerized tomography score (ASPECT) and the NIHSS scores at the first application and follow-up were analyzed. RESULTS: 28 of the patients were female and 42 were male and the mean age was 66.44 ± 13.47. Thirty-nine (55.7%) of the patients were referred to emergency services and 31 (44.3%) were directed to thrombolytic therapy from the emergency department of other hospitals. The initial NIHSS scores at the time of admission were 14.27 ± 4.26, while the NIHSS scores at the 24th hour were 11.47 ± 5.85. The ASPECT score at the time of admission was 9.61 ± 0.81. The median symptom-to-needle time was 89.5 minutes (0-245). The median door-to-needle time was 77 minutes (20-187). During thrombolytic application, edema occurred in 4 patients and intrahepatic hemorrhage occurred in 1 patient. At the end of the third month, 20 patients (28.5%) had complete recovery of neurological disability and 9 (12.9%) were exiting. DISCUSSION AND CONCLUSION: The results of this study show that IV-tPA treatment is a safe and effective treatment for acute ischemic stroke, similar to past studies, and that this treatment reduces the disability at the end of the third month.